Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities

Filiberto Cedeno-Laurent, Elisha M. Singer, Maria Wysocka, Bernice M. Benoit, Carmela C. Vittorio, Ellen J. Kim, Gil Yosipovitch, Alain H. Rook

Research output: Contribution to journalArticle

29 Scopus citations

Abstract

Pruritus is one of the cardinal symptoms found in patients with leukemic cutaneous T cell lymphoma (CTCL). The nature of the pruritus experienced by CTCL patients is complex, involving different pathways and cell mediators, thus making it poorly responsive to conventional anti-itch therapies. Recent reports highlight the role of interleukin 31 (IL-31) as a novel cytokine involved in the pathogenesis of pruritus in atopic dermatitis and CTCL. Here we provide both in vivo and in vitro evidence suggesting that histone deacetylase (HDAC) inhibitors may mitigate itch through lowering of levels of IL-31-expressing T cells. Furthermore, we demonstrate that chemokine receptor type-4 (CCR4)-bearing T cells are a main source of IL-31 in CTCL, and that neutralizing the IL-31 pathway through targeting of the CCR4-expressing T cells may represent a promising therapeutic strategy for symptomatic relief in CTCL.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalClinical Immunology
Volume158
Issue number1
DOIs
StatePublished - May 1 2015
Externally publishedYes

    Fingerprint

Keywords

  • CTCL
  • IL-31
  • Immunotherapy
  • Pruritus

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Cedeno-Laurent, F., Singer, E. M., Wysocka, M., Benoit, B. M., Vittorio, C. C., Kim, E. J., Yosipovitch, G., & Rook, A. H. (2015). Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. Clinical Immunology, 158(1), 1-7. https://doi.org/10.1016/j.clim.2015.02.014